x Acta Scientific | International Open Library | Open Access Journals Publishing Group

Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 4 Issue 8

The Potential Double-Faced Interactions of ACE Inhibitors/Blockers with SARS-COV-2 in Cardiovascular Diseases and Diabetes Mellitus Patients Who Developed COVID 19

Sara Ali*

Department of Zoology, Ain Shams University, Egypt

*Corresponding Author: Sara Ali, Department of Zoology, Ain Shams University, Egypt.

Received: July 01, 2020; Published: July 18, 2020

Reprints View PDF Related Articles

×

Abstract

 Coronaviruses (CoV) are a large family of viruses that cause illness that ranges from the common cold to more severe diseases. For instance, Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Ultimately, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for COVID-19, a global pandemic with disastrous ramifications for populations and healthcare systems on every side of world [1]. Since two decades, there have been outbreaks of severe, and even fatal in sometimes, resulted from human pathogenic CoVs. These CoV strains had originated in bats and were transmitted to humans via an intermediate host [1-3]. These strains displayed a stronger and quickly virulence transports from human to human. The CoVe-infection could usually produce mild symptoms, for particular individuals, responses were more severe in other cases could reach to death due to alveolar damage which finally lead to respiratory failure. During the current COVID 19 pandemic, it has been noticed that there is a number of patients who hospitalized by COVID-19 have high blood pressure as well as cardiovascular diseases (CVD). This number cannot be neglected, which could indicate to a somehow correlation between COVID 19 severity and these diseases. Recently, in an interview with a medical journal, the U.S. government’s top infectious disease expert Anthony Fauci cited a report showing similarly high rates of hypertension among COVID-19 patients who died in Italy and suggested the medicines such as angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) may act as an accelerant for the virus [4]. Contradictory, from animal studies, ARBs and ACEi have a potential protective effect of ARBs against lung injury in mice infected with SARS-CoV. Based on these findings and the similarities between SARS-CoV and the current SARS-CoV-2, it is thought that these drugs have the same potential protective effect against the severity of COVID 19. The question is, do ACEi/ARBs have a biphasic impact, do, is it regarded as a double-edged sword? Therefore, there is a concern that has been raised regarding whether ARBs and ACEIs would increase the morbidity and mortality of COVID-19 [5].

Keywords: ACE Inhibitors/Blockers; SARS-COV-2; Cardiovascular Diseases; Diabetes Mellitus and COVID 19

×

References

  1. Fehr AR and S Perlman. “Coronaviruses: an overview of their replication and pathogenesis”. Methods in Molecular Biology 1282 (2015): 1.
  2. Gu J and C Korteweg. “Pathology and pathogenesis of severe acute respiratory syndrome”. American Journal of Pathology 170 (2007): 1136.
  3. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273.
  4. By Deborah J Nelson. “Blood-pressure drugs are in the crosshairs of COVID-19”. (2020).
  5. Rami Sommerstein., et al. “Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?” Journal of the American Heart Association7 (2020).
  6. "Coronavirus disease 2019". World Health Organization: WHO (2020).
  7. Masters PS. “The molecular biology of coronavirus”. Advances in Virus Research 66 (2006): 193-292.
  8. Mortola E and Roy P. “Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system”. FEBS Letter 576 (2004): 174-178.
  9. Wang C., et al. “MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular immunity in rhesus macaques”. Oncotarget8 (2017): 12686-12694.
  10. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273.
  11. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 395 (2020): 565.
  12. Wan, Y., et al. “Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus”. Journal of Virology7 (2020): e00127-120.
  13. Li W., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature 426 (2003): 450.
  14. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. “The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19)—China, 2020”. China CDC Weekly 2 (2020): 113-122.
  15. Messerli FH., et al. “Angiotensin‐converting enzyme inhibitors in hypertension: to use or not to use?” Journal of the American College of Cardiology 71 (2018): 1474-1482.
  16. Hoffmann M., et al. “The novel coronavirus 2019 (2019‐nCoV) uses the SARS‐coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells”. bioRxiv (2020).
  17. Ferrario CM., et al. “Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2”. Circulation 111 (2005): 2605-2610.
  18. Sommerstein R and Gräni C. “Rapid response: re: preventing a covid‐19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid‐19”. BMJ (2020).
  19. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID‐19. (2020).
  20. Sukumaran V., et al. “Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade”. Biochemical Pharmacology 144 (2017): 90-99.
  21. European Societies of Cardiology. “Position statement of the ESC Council on Hypertension on ACE‐inhibitors and angiotensin receptor blockers” (2020).
  22. Giovanni de Simone. “Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers”. European Society of Cardiology (2020).
  23. Paul M., et al. “Physiology of local renin-angiotensin systems”. Physiology Review3 (2006): 747-803.
  24. Kopf P., et al. “Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries”. Endocrinology12 (2013): 4768-4776.
  25. Orfanos SE., et al. “Pulmonary capillary endothelium bound angiotensin-converting enzyme activity in acute lung injury”. Circulation16 (2000): 2011-2018.
  26. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis”. Journal of Pathology 203 (2004): 631-637.
  27. Sciarretta S., et al. “Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction”. Clinical Science6 (2009): 467-477.
  28. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China”. JAMA (2020).
  29. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
  30. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273.
  31. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell2 (2020): 271-280.
  32. Igase M., et al. “Angiotensin II AT1 receptors regulate ACE2 and angiotensin- (1-7) expression in the aorta of spontaneously hypertensive rats”. American Journal of Physiology-Heart and Circulatory Physiology 289 (2005): H1013-1039.
  33. Krishna Sriram., et al. “What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The experts explain”. Academic rigour, journalistic flair (2020).
  34. Vaduganathan M., et al. “Renin-angiotensin-aldosterone system Iinhibitors in patients with Covid-19”. The New England Journal of Medicine 382 (2020): 1653-1659.
  35. Liu J., et al. “Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARSCoV, MERS-CoV, and 2019- nCoV”. Journal of Medical Virology 5 (2020): 491-494.
  36. Sparks MA., et al. “Classical renin- angiotensin system in kidney physiology”. Comprehensive Physiology 3 (2014): 1201-1228.
  37. Nahum LH. “The renin angiotensin-aldosterone system (RAAS) in normal man”. Connecticut Medicine 10 (1965): 710-711.
  38. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell 2 (2020): 271-280.
  39. Watkins J. “Preventing a covid-19 pandemic”. BMJ 368 (2020): m810.
  40. Ferrario CM., et al. “Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin converting enzyme 2”. Circulation 20 (2005): 2605-2610.
  41. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine (2020).
  42. Guo T., et al. “Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)”. JAMA Cardiology (2020).
  43. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China”. JAMA Cardiology (2020).
  44. Santos RAS., et al. “The ACE2/angiotensin- (1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin- (1-7)”. Physiology Review 98 (2018): 505-553.
  45. Sun ML., et al. “Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia”. Zhonghua Jie He He Hu Xi Za Zhi3 (2020): 219-222.
  46. Yang G., et al. “Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension”. medRxiv (2020).
  47. “Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician”. Heart (2020).
  48. Fang L., et al. “Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?” Lancet Respiratory Medicine 4 (2020): PE21.
  49. Li XC., et al. “The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases”. Pharmacology Research 125 (2017): 21-38.
  50. Kuba K., et al. “A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury”. Nature Medicine 11 (2005): 875-879.
  51. Andrew M South., et al. “Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic”. Nature Reviews Nephrology 16 (2020): 305-307.
×

Citation

Citation: Sara Ali. “The Potential Double-Faced Interactions of ACE Inhibitors/Blockers with SARS-COV-2 in Cardiovascular Diseases and Diabetes Mellitus Patients Who Developed COVID 19". Acta Scientific Pharmaceutical Sciences 4.8 (2020): 31-39.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US





+91 9182824667

     info@acta-scientific.com

Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.